Literature DB >> 21496888

Poly(ADP-ribose) polymerase is involved in the development of diabetic cystopathy via regulation of nuclear factor kappa B.

Wen Ji Li1, Mi-Kyung Shin, Seung-June Oh.   

Abstract

OBJECTIVES: To investigate whether overactivated Poly (ADP-ribose) polymerase (PARP) and subsequent activation of nuclear factor kappa B (NF-κB) correlate with the development of diabetic cystopathy via induction of bladder apoptosis. Diabetic cystopathy as a common complication of diabetes is frequently associated with increased oxidative stress and apoptosis of the bladder. PARP is activated by hyperglycemia-induced oxidative stress and plays a critical role in cell apoptosis and the development of diabetic complications, such as retinopathy and nephropathy.
METHODS: Sprague-Dawley rats were divided into 3 groups: control, diabetic, and diabetic treated with PARP inhibitor (DM+Vit-B3). Four weeks after induction of diabetes, the DM+Vit-B3 group was treated with PARP inhibitor (nicotinamide, 400 mg/kg/d) for 3 weeks. Bladder function was then assessed by conscious cystometry. The extent of oxidative stress and apoptosis, expression of poly(ADP-ribose) (PAR), NF-κB, phosphorylated inhibitor of NF-κB (IκB)-α, Bcl-2, and Bax in the bladder were also investigated.
RESULTS: Bladder dysfunction was strongly associated with increased oxidative stress and bladder apoptosis. In addition, the amount of PAR, phosphorylated IκB-α, expression of NF-κB, and Bax were significantly increased in diabetic rat bladder. Inhibition of PARP significantly reduced PARP activation and expression of NF-κB and Bax. As a result, bladder apoptosis was attenuated and bladder function was improved.
CONCLUSIONS: These results indicate that overactivated PARP and subsequent activation of NF-κB play important roles in the development of diabetic cystopathy via induction of bladder apoptosis. These findings may be applied in the development of novel therapies for patients with diabetic cystopathy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21496888     DOI: 10.1016/j.urology.2011.01.022

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Glucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity.

Authors:  Fei Yan; Guang-Hao Zhang; Min Feng; Wei Zhang; Jia-ning Zhang; Wen-qian Dong; Cheng Zhang; Yun Zhang; Li Chen; Ming-Xiang Zhang
Journal:  Mol Med       Date:  2015-02-10       Impact factor: 6.354

Review 2.  Research Findings on Overactive Bladder.

Authors:  Phani B Patra; Sayani Patra
Journal:  Curr Urol       Date:  2015-05-20

3.  Smooth muscle-specific deletion of MnSOD exacerbates diabetes-induced bladder dysfunction in mice.

Authors:  Rania A Elrashidy; Michael Kavran; Mervat E Asker; Hoda E Mohamed; Firouz Daneshgari; Guiming Liu
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

Review 4.  Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.

Authors:  Seon Beom Song; Jin Sung Park; Gu June Chung; In Hye Lee; Eun Seong Hwang
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

5.  microRNA-128 mediates CB1 expression and regulates NF-KB/p-JNK axis to influence the occurrence of diabetic bladder disease.

Authors:  Xin Gou; Jing Wu; Mingqing Huang; Yuting Weng; Tongxin Yang; Tao Chen; Guiqing Li; Kewei Fang
Journal:  J Transl Med       Date:  2020-07-16       Impact factor: 5.531

6.  Management of lower urinary tract dysfunction in patients with neurological disorders.

Authors:  Wen Ji Li; Seung-June Oh
Journal:  Korean J Urol       Date:  2012-09-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.